Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOXIL/CAELYX + VELCADE versus VELCADE alone in relapsed multiple myeloma
2004-001842-34Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing DOXIL/CAELYX + VELCADE with VELCADE monotherapy (2 arms). Primary endpoint: Time to progression. Started Oct 2004; status: completed.
02
Drugs
doxorubicinbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2004-001842-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001842-34.